



PRESS RELEASE

## **Additional terbinafine supplier approved**

**STOCKHOLM, March 13<sup>th</sup>, 2026. Moberg Pharma AB (OMX:MOB) today announces that an additional supplier of terbinafine has been approved for MOB-015 (drug for nail fungus). The regulatory approval process, initiated in April 2024, has now been positively completed.**

As a result, Moberg Pharma has thereby secured two alternative suppliers of terbinafine, each with the capacity to meet the company's global demand for terbinafine. This is in line with the company's overall quality efforts, ensuring a stable supply of the active ingredient.

**For additional information, please contact:**

Anna Ljung, CEO, Phone: +46 8 522 307 01, e-mail: [anna.ljung@mobergpharma.se](mailto:anna.ljung@mobergpharma.se)

**About this information**

The information was submitted for publication, through the agency of the contact person set out above, on March 13<sup>th</sup>, 2026, at 3:00 pm CET.

**About Moberg Pharma, [www.mobergpharma.com](http://www.mobergpharma.com)**

Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's drug MOB-015 is a novel topical treatment for onychomycosis (nail fungus) with market approval in 13 EU countries. MOB-015 is sold in Sweden and Norway under the brand name Terclara<sup>®</sup> and is available at all pharmacy chains. Phase 3 clinical trials for MOB-015 involving more than 800 patients indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the company's shares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB).